You are here

Glycoengineered baculoviruses for the production of more efficacious influenza va

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI112118-01
Agency Tracking Number: R43AI112118
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1938 Harney St
LARAMIE, WY 82072-3037
United States
DUNS: 968784103
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 AJAYKUMAR MAGHODIA
 (307) 760-8194
 ajay.maghodia@gmail.com
Business Contact
 DONALD JARVIS
Phone: (307) 760-8194
Email: DLJarvis@uwyo.edu
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Vaccination significantly reduces morbidity and mortality caused by annual influenza epidemics. Traditionally, influenza vaccines have been manufactured using adapted influenza virus grown in eggs. However, this methodsuffers from inherent disadvantages such as slow production and allergenic egg proteins in the final product. To avoid these drawbacks, new vaccines made of recombinant hemagglutinin produced in the baculovirus/insect cell system (BICS) have been developed. Although effective, the BICS product has reduced immunogenicity compared to the egg-product, resulting in 3-fold higher vaccine doses and cost. The most distinct difference between egg-produced and BICS-produced hemagglutinin (HA) is the structure of their carbohydrate side-chains, or glycans. The egg product has complex, branched glycans containing galactose, whereas the BICS product has truncated, insect-type glycans without galactose. Recent vaccination studies clearly demonstrate that HA with eg

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government